Results 1 to 10 of about 13,920 (120)
Fingolimod and Diabetic Retinopathy: A Drug Repurposing Study
Frontiers in Pharmacology, 2021 This study aimed to investigate the interactions between fingolimod, a sphingosine 1-phosphate receptor (S1PR) agonist, and melanocortin receptors 1 and 5 (MCR1, MCR5).
Carlo Gesualdo +17 more
doaj +1 more source
Applied Sciences, 2022 Fingolimod is a sphingosine 1-phosphate-receptor modulator approved for the oral treatment of relapsing–remitting multiple sclerosis (RRMS), a form of MS characterized by a pattern of exacerbation of neurological symptoms followed by recovery.
Claudia Fracasso +6 more
doaj +1 more source
Fingolimod increases parvalbumin-positive neurons in adult mice
IBRO Neuroscience Reports, 2022 In recent years, it has been shown that central nervous system agents, such as antidepressants and antiepileptic drugs, reopen a critical period in mature animals.
Hiroshi Ueno +6 more
doaj +1 more source
Fingolimod‐induced bladder lymphoma in a patient with multiple sclerosis
Clinical Case Reports, 2023 Key Clinical Message Malignancies were reported in some studies following taking Fingolimod. We reported a case of bladder lymphoma after taking Fingolimod. Physicians should consider the carcinogenic effects of Fingolimod in long‐term use and replace it
Saeed Vaheb +3 more
doaj +1 more source
The antiinflammatory and electrophysiological effects of fingolimod on penicillin-induced rats
Arquivos de Neuro-Psiquiatria, 2022 Background The fact that inflammation triggers epileptic seizures brings to mind the antiepileptic properties of anti-inflammatory drugs. Objective To investigate the electrophysiological and anti-inflammatory effects of fingolimod on an ...
Canan Akünal Türel +4 more
doaj +1 more source
Fingolimod prevents blood-brain barrier disruption induced by the sera from patients with multiple sclerosis. [PDF]
PLoS ONE, 2015 OBJECTIVE: Effect of fingolimod in multiple sclerosis (MS) is thought to involve the prevention of lymphocyte egress from lymphoid tissues, thereby reducing autoaggressive lymphocyte infiltration into the central nervous system across blood-brain barrier
Hideaki Nishihara +7 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Preclinical data indicate that fingolimod improves outcome post-ischaemia. This study used a rigorous study design in normal male C57BL/6JOlaHsd mice and in mice with common stroke comorbidities to further evaluate the translational potential of ...
Andrea C. Diaz Diaz +6 more
doaj +1 more source
Exploratory Research in Clinical and Social Pharmacy, 2021 Background: Fingolimod is the first approved oral disease-modifying agent (DMA) in 2010 to treat Multiple Sclerosis (MS). There is limited real-world evidence regarding the determinants associated with fingolimod use in the early years.
Jagadeswara Rao Earla +5 more
doaj +1 more source
Frontiers in Neuroscience, 2021 Favorable effects exerted by long-term administration of fingolimod therapy in multiple sclerosis (MS) patients have been reported, but sporadic side effects, such as reversible macular edema, also have been recorded. The present study aimed to determine
Tao Yang +8 more
doaj +1 more source
Fingolimod Promotes Antibacterial Effect of Doripenem against Carbapenem-Resistant Escherichia coli
Antibiotics, 2022 The aim of this study was to determine whether fingolimod could synergize the antibacterial activity of doripenem against carbapenem-resistant Escherichia coli (CREC) and its potential as an antibiotic adjuvant for doripenem. The E.
Hye-Won Jin, Hye-Rim Kim, Yong-Bin Eom
doaj +1 more source